Lucentis 10 mg/ml solution for injection, FARICIMAB
CR44829
Phase 3 small_molecule active
Quick answer
Lucentis 10 mg/ml solution for injection, FARICIMAB for Choroidal neovascularization secondary to pathologic myopia is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Choroidal neovascularization secondary to pathologic myopia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active